Patient, if not long-suffering, shareholders in Rochester Medical (ROCM) finally got their vindication on Wednesday, as Bard (BCR) stepped up with an all-cash offer for this largely home-care focused urology devices company. Although this deal is not going to radically change the growth outlook for Bard, it is a logical buy-vs-build move that should add long-term value and give the company entry into a market that should be poised for growth in the coming years.
Farewell, And Thanks For The Profits
Rochester Medical announced that it had received and accepted a $262 million all-cash deal from Bard worth $20 per share. That gives Rochester Medical shareholders a 45% premium to Tuesday's close, and the...
Only subscribers can access this article, which is part of the PRO research library covering 3,554 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: